The Pharmaceutical Squeeze: Lower Prices and Higher Tariffs at Once
Twenty-six manufacturers have signed most-favored-nation pricing deals. On 29 September, tariffs on patented medicines reach every remaining company.
American pharmaceutical policy is currently running two programmes that pull against each other.
Programme one: prices down
President Trump announced agreements with nine additional manufacturers on 31 August, bringing to 26 the number with most-favored-nation arrangements — tying US prices to what comparable wealthy countries pay.
The rationale is that Americans have long paid substantially more than other high-income markets for the same branded medicines.
Programme two: costs up
Tariffs on certain patented pharmaceuticals and their associated ingredients took effect for some companies on 31 July 2026, and reach all remaining companies on 29 September.
Medicines are an unusual tariff target for three reasons:
- Demand is inelastic — patients do not consume less of a prescribed drug when it costs more.
- Substitution is often impossible — a patented medicine has no direct equivalent by definition.
- Ingredient supply is concentrated — active ingredients come from a small number of global facilities.
Where demand cannot fall and substitutes do not exist, a tariff is paid by purchasers rather than absorbed by a foreign producer losing sales.
The ingredient provision
Extending duties to associated pharmaceutical ingredients is the sharper edge. Because active ingredients are shipped to formulation facilities including domestic ones, the tariff can raise costs for medicines finished in the United States — the opposite of a protective tariff's intended effect.
Can both work at once?
In principle, yes: benchmark pricing constrains what manufacturers may charge, while tariffs alter their input costs. In practice the pressure lands on margins from both directions simultaneously, and companies have a limited set of responses.
The one health systems worry about is withdrawal — pulling specific products from the US market where the combined effect makes them uneconomic. That tends to hit older, lower-margin medicines first, which are frequently the ones with no alternative.
What to watch after 29 September
Not list prices, which respond slowly and are obscured by the rebate system, but supply. Shortage notices are the indicator that would show the two programmes colliding.